Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Letter

Response to ‘Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study’

Katsunori Ikari*, Koichiro Yano, Shinji Yoshida, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki Momohara

Author Affiliations

Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada, Shinjuku 162-0054, Tokyo, Japan

For all author emails, please log on.

Arthritis Research & Therapy 2014, 16:422  doi:10.1186/s13075-014-0422-3

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/16/5/422


Published:27 August 2014

© 2014 Ikari et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

No abstract

Letter

Rheumatoid arthritis (RA) is a complex polygenic disease characterized by progressive joint destruction. Anti-citrullinated peptide antibody (ACPA) is the most specific autoantibody for RA. Genetic polymorphisms in the PADI4 gene, encoding citrullinating enzyme peptidylarginine deiminase 4 (PADI4), have been associated with susceptibility to RA [1],[2]. They have also been reported to be associated with radiographic joint destruction in patients with RA [3],[4]. We focused on ACPA-negative RA patients to investigate whether a PADI4 polymorphism is associated with joint damage in ACPA-negative patients.

DNA samples from 122 Japanese ACPA-negative RA patients were used for the study; 81.1% were female, 51.6% were rheumatoid factor (RF)-positive, and the mean age was 55 years. Sharp/van der Heijde score of the hands at a 5-year disease duration, which represents joint damage, was scored and log-transformed as described elsewhere [4]. Single-nucleotide polymorphism (SNP) rs2240340 was selected and genotyped by using a TaqMan method as described elsewhere [4]. The genetic risk of joint damage associated with rs2240340 was assessed by multiple regression analysis adjusted for HLA-DRB1 shared-epitope alleles and RF that are thought to be associated with joint damage in patients with RA [4].

The PADI4 SNP was significantly associated with radiographic joint destruction in the ACPA-negative RA patients in a recessive model (P = 0.0287) (Table 1 and Figure 1). The overall genotyping success rate was 99.2% and the genotype concordance rate was 100% as assessed by duplicate samples. Although the sample size is one of the major limitations to the study of ACPA-negative patients because of the high positivity of ACPA (up to 90%) in RA populations, we were able to collect DNA samples from 122 ACPA-negative RA patients with radiographic data.

Table 1. Association ofPADI4SNP (recessive model) with Sharp/van der Heijde score of hands at 5-year disease duration in ACPA-negative RA patients

thumbnailFigure 1. Boxplots representing the distribution of Sharp/van der Heijde score of hands at 5-year disease duration according to the number of the susceptibility allele of rs2240340 (minor allele, A) in thePADI4locus. Each box represents the interquartile range of values, and the bold line shows the median value. The vertical lines show maximum and minimum values that fall within 1.5 box lengths, and the open circles show extreme values of more than 1.5 boxplot lengths. PADI4, peptidylarginine deiminase 4; SHS, Sharp/van der Heijde score.

PADI4 encodes citrullinating enzymes that may play an important role in ACPA formation. It has been shown that PADI4 alleles were associated with the presence of ACPA in patients with RA [1]. In the present study, we have shown that PADI4 polymorphism contributes to joint destruction in ACPA-negative RA patients. A recent study has suggested that PADI4 gene contributes to the development of RA, regardless of ACPA status [3]. We have also reported that the PADI4 risk allele has an impact on joint damage after adjustment for ACPA status [4]. The PADI4 gene is likely to play a role in the disease progression of RA in addition to its role in ACPA formation. The results of this study provide important knowledge of the risks on progressive joint damage in patients with RA.

Abbreviations

ACPA: Anti-citrullinated peptide antibody

PADI4: Peptidylarginine deiminase 4

RA: Rheumatoid arthritis

RF: Rheumatoid factor

SNP: Single-nucleotide polymorphism

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by grants provided by the Japanese Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research (to KI) and the Japanese Ministry of Health, Labour and Welfare (to SM and HY). We thank all DNA donors for making this study possible. We appreciate the members of Institute of Rheumatology of the Tokyo Women’s Medical University for their effort in the Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort. We are grateful to Noriko Iikuni for her assistance in preparing the manuscript and to Yuta Kochi and Akari Suzuki for their advice.

References

  1. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.

    Nat Genet 2003, 34:395-402. PubMed Abstract | Publisher Full Text OpenURL

  2. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, et al.: Genetics of rheumatoid arthritis contributes to biology and drug discovery.

    Nature 2014, 506:376-381. PubMed Abstract | Publisher Full Text OpenURL

  3. Bang SY, Han TU, Choi CB, Sung YK, Bae SC, Kang C: Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study.

    Arthritis Res Ther 2010, 12:R115. PubMed Abstract | BioMed Central Full Text OpenURL

  4. Suzuki T, Ikari K, Yano K, Inoue E, Toyama Y, Taniguchi A, Yamanaka H, Momohara S: PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study.

    PloS One 2013, 8:e61045. PubMed Abstract | Publisher Full Text OpenURL